AQST - Aquestive Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Warren,
United States
Type: Equity
AQST price evolution
AQST
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $23.87 | $24.92 | $22.44 | $26.88 |
| Short term investments | ||||
| Net receivables | $8.47 | $8.55 | $10.1 | $7.55 |
| Inventory | $6.77 | $7.08 | $5.95 | $6.98 |
| Total current assets | $40.97 | $42.46 | $39.79 | $43.71 |
| Long term investments | ||||
| Property, plant & equipment | $9.74 | $10.22 | $10.38 | $9.7 |
| Goodwill & intangible assets | $1.28 | $1.32 | $1.36 | $1.4 |
| Total noncurrent assets | $16.45 | $16.99 | $17.21 | $17.58 |
| Total investments | ||||
| Total assets | $57.42 | $59.45 | $56.99 | $61.28 |
| Current liabilities | ||||
| Accounts payable | $8.93 | $9.99 | $10.69 | $12.44 |
| Deferred revenue | $33.9 | $35.37 | $37.11 | $37.8 |
| Short long term debt | $1.33 | $5.96 | $19.71 | $18.67 |
| Total current liabilities | $18.31 | $24.06 | $38.65 | $40.38 |
| Long term debt | $111.24 | $103.58 | $89.87 | $95.04 |
| Total noncurrent liabilities | $145.6 | $138.32 | $124.99 | $130.14 |
| Total debt | $112.57 | $109.53 | $109.58 | $113.71 |
| Total liabilities | $163.91 | $162.38 | $163.65 | $170.52 |
| Shareholders' equity | ||||
| Retained earnings | -$319.08 | -$310.97 | -$308.93 | -$303.14 |
| Other shareholder equity | ||||
| Total shareholder equity | -$106.49 | -$102.93 | -$106.65 | -$109.23 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $23.87 | $27.27 | $28.02 | $31.81 |
| Short term investments | ||||
| Net receivables | $8.47 | $4.7 | $12.12 | $6.96 |
| Inventory | $6.77 | $5.78 | $4.04 | $2.46 |
| Total current assets | $40.97 | $39.89 | $47.26 | $44.63 |
| Long term investments | ||||
| Property, plant & equipment | $9.74 | $7.9 | $7.78 | $10.32 |
| Goodwill & intangible assets | $1.28 | $1.44 | $0.05 | $0.1 |
| Total noncurrent assets | $16.45 | $17.18 | $14.73 | $18.26 |
| Total investments | ||||
| Total assets | $57.42 | $55.67 | $61.99 | $62.88 |
| Current liabilities | ||||
| Accounts payable | $8.93 | $9.95 | $8.31 | $7.09 |
| Deferred revenue | $33.9 | $32.93 | $7.89 | $4.33 |
| Short long term debt | $1.33 | $20.1 | $4.15 | $4.75 |
| Total current liabilities | $18.31 | $39.68 | $21.96 | $21.1 |
| Long term debt | $111.24 | $33.45 | $112.56 | $84.7 |
| Total noncurrent liabilities | $145.6 | $136.1 | $122.16 | $90.28 |
| Total debt | $112.57 | $122.75 | $116.7 | $89.45 |
| Total liabilities | $163.91 | $174.23 | $144.13 | $111.38 |
| Shareholders' equity | ||||
| Retained earnings | -$319.08 | -$311.21 | -$256.8 | -$186.26 |
| Other shareholder equity | ||||
| Total shareholder equity | -$106.49 | -$118.55 | -$82.13 | -$48.5 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $13.21 | $13 | $13.24 | $11.13 |
| Cost of revenue | $4.68 | $4.8 | $6.62 | $4.74 |
| Gross Profit | $8.53 | $8.2 | $6.62 | $6.4 |
| Operating activities | ||||
| Research & development | $2.89 | $3.2 | $3.47 | $3.55 |
| Selling, general & administrative | $9.55 | $7.38 | $7.36 | $7.46 |
| Total operating expenses | $12.44 | $10.58 | $10.83 | $11 |
| Operating income | -$3.91 | -$2.38 | -$4.21 | -$4.61 |
| Income from continuing operations | ||||
| EBIT | -$4.78 | -$0.86 | -$4.08 | $9.55 |
| Income tax expense | $0.1 | -$0.14 | $0.28 | |
| Interest expense | $3.23 | $1.31 | $1.43 | $1.49 |
| Net income | ||||
| Net income | -$8.11 | -$2.04 | -$5.79 | $8.07 |
| Income (for common shares) | -$8.11 | -$2.04 | -$5.79 | $8.07 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $50.58 | $47.68 | $50.83 | $45.85 |
| Cost of revenue | $20.83 | $19.39 | $14.99 | $12.96 |
| Gross Profit | $29.75 | $28.29 | $35.84 | $32.88 |
| Operating activities | ||||
| Research & development | $13.1 | $17.48 | $17.05 | $19.89 |
| Selling, general & administrative | $31.75 | $52.88 | $53.48 | $55.89 |
| Total operating expenses | $44.85 | $70.36 | $70.52 | $75.78 |
| Operating income | -$15.1 | -$42.07 | -$34.68 | -$42.89 |
| Income from continuing operations | ||||
| EBIT | -$0.16 | -$41.97 | -$48.08 | -$42.76 |
| Income tax expense | $0.24 | |||
| Interest expense | $7.46 | $12.44 | $22.46 | $13.02 |
| Net income | ||||
| Net income | -$7.87 | -$54.41 | -$70.54 | -$55.78 |
| Income (for common shares) | -$7.87 | -$54.41 | -$70.54 | -$55.78 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$8.11 | -$2.04 | -$5.79 | $8.07 |
| Operating activities | ||||
| Depreciation | $0.47 | $0.26 | $0.29 | $0.33 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.94 | $0.77 | $0.63 | $0.34 |
| Total cash flows from operations | -$4.94 | -$2.35 | -$7.91 | $8.82 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.15 | -$0.83 | -$0 |
| Investments | ||||
| Total cash flows from investing | -$0.02 | -$0.15 | -$0.83 | -$0 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.61 | $4.98 | $7.75 | $0.92 |
| Net borrowings | $0.3 | -$0.01 | -$3.46 | -$10.11 |
| Total cash flows from financing | $3.91 | $4.98 | $4.29 | -$9.21 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.04 | $2.48 | -$4.45 | -$0.39 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$7.87 | -$54.41 | -$70.54 | -$55.78 |
| Operating activities | ||||
| Depreciation | $1.34 | $2.39 | $2.96 | $3.44 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.69 | $4.38 | $6.82 | $6.58 |
| Total cash flows from operations | -$6.38 | -$9.79 | -$32.98 | -$45.46 |
| Investing activities | ||||
| Capital expenditures | -$0.99 | -$2.52 | -$0.91 | -$0.52 |
| Investments | ||||
| Total cash flows from investing | -$0.99 | -$2.52 | -$0.91 | -$0.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.26 | $13.59 | $30.12 | $6.21 |
| Net borrowings | -$13.27 | -$2.02 | $22.34 | |
| Total cash flows from financing | $3.97 | $11.56 | $30.11 | $28.46 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.4 | -$0.75 | -$3.78 | -$17.52 |
News
Fundamentals
| Market cap | $281.33M |
|---|---|
| Enterprise value | $370.03M |
| Shares outstanding | 68.53M |
| Revenue | $50.58M |
|---|---|
| EBITDA | $1.18M |
| EBIT | -$163.00K |
| Net Income | -$7.87M |
| Revenue Q/Q | 23.63% |
| Revenue Y/Y | 6.09% |
| P/E ratio | -35.75 |
|---|---|
| EV/Sales | 7.32 |
| EV/EBITDA | 313.05 |
| EV/EBIT | -2.27K |
| P/S ratio | 5.56 |
| P/B ratio | -2.64 |
| Book/Share | -1.55 |
| Cash/Share | 0.35 |
| EPS | -$0.11 |
|---|---|
| ROA | -13.39% |
| ROE | 7.40% |
| Debt/Equity | -1.54 |
|---|---|
| Net debt/EBITDA | 118.47 |
| Current ratio | 2.24 |
| Quick ratio | 1.87 |